Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wedbush Maintains Neutral on Praxis Precision Medicine, Raises Price Target to $48

Author: Benzinga Newsdesk | August 14, 2024 01:38pm
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Neutral and raises the price target from $40 to $48.

Posted In: PRAX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist